Current treatment status-Undergoing active treatment-Progressive despite several lines of treatment - Page 10 of 24 Posts on Medivizor
Navigation Menu

Current treatment status-Undergoing active treatment-Progressive despite several lines of treatment Posts on Medivizor

Looking for postmenopausal women with advanced breast cancer to try a hormonal therapy

Posted by on Oct 24, 2019 in Breast cancer | 0 comments

In a nutshell This study is looking for postmenopausal patients with advanced breast cancer with an ESR1 mutation to compare lasofoxifene (Fablyn) to fulvestrant (Faslodex). The main outcome measured in this trial will be the patient’s survival without tumor growth or spread. This trial is recruiting in multiple locations in the United...

Read More

Evaluating combination CAR-T cell therapy for recurrent or treatment-resistant multiple myeloma

Evaluating combination CAR-T cell therapy for recurrent or treatment-resistant multiple myeloma

Posted by on Oct 6, 2019 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of combining two T-cell therapies for multiple myeloma (MM) that has come back or stopped responding to treatment. This study concluded that this treatment showed promising effectiveness for these patients. Some background Treatment for patients with MM that has come back (relapsed)...

Read More

Looking for patients with relapsed or unresponsive multiple myeloma to try allogeneic CAR-T cell therapy

Looking for patients with relapsed or unresponsive multiple myeloma to try allogeneic CAR-T cell therapy

Posted by on Sep 30, 2019 in Multiple Myeloma | 0 comments

In a nutshell This trial is evaluating the safety and effectiveness of allogeneic CAR-T cell therapy (ALLO-715) in patients with multiple myeloma (MM) that has come back or stopped responding to treatment. The main outcome to be measured will be the number of patients who have side effects. This trial is recruiting in Denver, CO. The details Chimeric...

Read More

Searching for patients with relapsed/unresponsive non-Hodgkin lymphoma to test an experimental antibody drug

Posted by on Sep 25, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study is examining the effects of IGM-2323 for certain types of relapsed/unresponsive non-Hodgkin lymphoma. The main outcomes that will be measured are the side effects experienced by patients and the effectiveness of treatment. This trial is recruiting in the United States. The details Non-Hodgkin lymphoma (NHL) is a...

Read More

Nivolumab in previously treated advanced non-small cell lung cancer – what is the long-term outlook for survival?

Nivolumab in previously treated advanced non-small cell lung cancer – what is the long-term outlook for survival?

Posted by on Sep 16, 2019 in Lung cancer | 0 comments

In a nutshell This study investigated survival rates in advanced non-small cell lung cancer (NSCLC) after nivolumab (Opdivo) treatment.  They found that nivolumab was associated with longer survival time in patients that responded to treatment.  Some background Lung cancer (LC) is one of the most common cancers worldwide. Non-small...

Read More

Evaluating the TLI-ATG conditioning regimen before allogeneic stem cell transplantation in patients with lymphoma or leukemia

Evaluating the TLI-ATG conditioning regimen before allogeneic stem cell transplantation in patients with lymphoma or leukemia

Posted by on Sep 13, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of total lymphoid irradiation and anti-thymocyte globulin (TLI-ATG) conditioning before stem cell transplantation (SCT) in patients with lymphoma or leukemia. This study concluded that this regimen was well-tolerated and effective, especially for patients who had multiple lines of prior...

Read More

Evaluating Kd and Vd chemotherapy for patients with relapsed or refractory multiple myeloma

Evaluating Kd and Vd chemotherapy for patients with relapsed or refractory multiple myeloma

Posted by on Aug 27, 2019 in Multiple Myeloma | 0 comments

In a nutshell This study compared the effectiveness of Kd (carfilzomib, dexamethasone) chemotherapy to Vd (bortezomib, dexamethasone) chemotherapy in patients with multiple myeloma (MM). This study found that Kd improved survival outcomes and had fewer side effects compared to Vd chemotherapy for these patients. Some background Multiple...

Read More

Looking for patients with relapsed or unresponsive multiple myeloma to test a new antibody drug

Looking for patients with relapsed or unresponsive multiple myeloma to test a new antibody drug

Posted by on Aug 14, 2019 in Multiple Myeloma | 0 comments

In a nutshell This study is examining the effectiveness of antibody drug tiragolumab with or without standard treatment for relapsed or unresponsive multiple myeloma or non-Hodgkin lymphoma. The main outcome would be the side effects experienced by patients 1 year after treatment.  The details Both multiple myeloma (MM) and non-Hodkin lymphoma...

Read More

Evaluating BCD chemotherapy for patients with peripheral T-cell lymphoma

Evaluating BCD chemotherapy for patients with peripheral T-cell lymphoma

Posted by on Jul 31, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of BCD chemotherapy (bendamustine, carboplatin, and dexamethasone) for patients with peripheral T-cell lymphoma that has come back or stopped responding to treatment. This study concluded that this treatment was promising, with minimal side effects. Some background Peripheral T-cell...

Read More